Triple GIP, GLP-1 and glucagon receptor agonist
UnapprovedRetatrutide: an investigational drug, not an available one
Retatrutide is not approved by the FDA. It is an investigational triple agonist in clinical development by Eli Lilly. Because it is an investigational drug it cannot lawfully be compounded, and no licensed prescriber can write for it outside a trial.
Where this stands
Investigational. The FDA has named retatrutide specifically in enforcement against compounders and sellers using a "research use only" label. This page exists because the search demand is large and every commercial result answering it is selling something unlawful.
We do not link to sellers of unapproved compounds, we do not name vendors, and we publish no dosing for them.
Key facts
- Approval status
- Investigational, not approved
- Can it be compounded?
- No. An investigational drug cannot be compounded
Sources
Every claim above is checked against the primary text, and the date is the day we last opened it.
-
1
Warning Letter: Gram Peptides (MARCS-CMS 721806)
U.S. Food and Drug Administration, CDER Primary text read and checked Checked August 25, 2026